ライフサイエンスコーパス: therapeutic agent

1 r-modifying effect of amphiphiles (including therapeutic agents).

2 s a potential breast cancer preventative and therapeutic agent.

3 Pr20 is an immunological tool and potential therapeutic agent.

4 previously unrecognized indication for this therapeutic agent.

5 c mechanism that can be targeted using a new therapeutic agent.

6 nued investigation of this already-available therapeutic agent.

7 egulator of innate immunity and an important therapeutic agent.

8 n the environment following excretion of the therapeutic agent.

9 anoparticles (SP141FcNP) as an orally cancer therapeutic agent.

10 flammation as well as its potential use as a therapeutic agent.

11 and tested in the clinic as potential cancer therapeutic agents.

12 al resilience may help in the search for new therapeutic agents.

13 portant mental functions but lacks efficient therapeutic agents.

14 assessing cell-based targeting of effective therapeutic agents.

15 terials, biorecognition, nanomachines and as therapeutic agents.

16 nces of somatic mutations and the testing of therapeutic agents.

17 ficacy and reduction in tolerance of several therapeutic agents.

18 tors both as chemical tools and as potential therapeutic agents.

19 ge to targeted delivery of diagnostic and/or therapeutic agents.

20 ential as in vivo pharmacological probes and therapeutic agents.

21 d solubility has prevented implementation as therapeutic agents.

22 fector mechanisms and provide more effective therapeutic agents.

23 l potential as targets for new antibacterial therapeutic agents.

24 future development of this emerging class of therapeutic agents.

25 f these small molecules as clinically useful therapeutic agents.

26 portantly, allow the future testing of novel therapeutic agents.

27 t critical steps suggests their potential as therapeutic agents.

28 serve as the basis for development of future therapeutic agents.

29 ogy and for preclinical testing of potential therapeutic agents.

30 hich is typified by the absence of effective therapeutic agents.

31 y of this canine model of AD for testing new therapeutic agents.

32 he past three decades as pharmacological and therapeutic agents.

33 s great potential as both research tools and therapeutic agents.

34 of novel classes NMDA receptor modulators as therapeutic agents.

35 MDA receptors should aid in designing better therapeutic agents.

36 ered RNAs as a novel class of large molecule therapeutic agents.

37 ve compounds, used as spin-trap reagents and therapeutic agents.

38 regulation as well as the development of new therapeutic agents.

39 of the genetic diversity of PDAs to develop therapeutic agents.

40 ment and maintenance, are becoming promising therapeutic agents.

41 s undermined during tumor progression and by therapeutic agents.

42 thogenic role of genes and for testing novel therapeutic agents.

43 ul implementation in diagnostic assays or as therapeutic agents.

44 y as biomedical imaging probes and potential therapeutic agents.

45 void cross resistance against currently used therapeutic agents.

46 ing only CB1 receptor blockers may be useful therapeutic agents.

47 o promote the development of these promising therapeutic agents.

48 d signals regulate local release of specific therapeutic agents.

49 ting in toxicity that precludes their use as therapeutic agents.

50 r the development of novel anti-inflammatory therapeutic agents.

51 s for spatio-temporal controlled delivery of therapeutic agents.

52 lopment of novel plant protection agents and therapeutic agents.

53 stimulated efforts designed to identify new therapeutic agents.

54 ntibodies (bnAbs) could in the future become therapeutic agents.

55 f biliary disorders and the testing of novel therapeutic agents.

56 ical development have shown promise as novel therapeutic agents.

57 interest in developing activators of KCC2 as therapeutic agents.

58 novel antibiotic targets and to discover new therapeutic agents.

59 of 1,20S(OH)2D3 and its analogs as potential therapeutic agents.

60 ate vaccine targets and are prophylactic and therapeutic agents.

61 of global TGF-beta1 signaling inhibitors as therapeutic agents.

62 f targeting MT dynamics in the design of new therapeutic agents.

63 ers as yet uncharacterized for potential new therapeutic agents.

64 rs are frequently used as experimental viral therapeutic agents.

65 r effectors, may provide chemical probes and therapeutic agents.

66 ountered in bioactive compounds and approved therapeutic agents.

67 ukemic cells and influence their response to therapeutic agents.

68 kages are broadly used as research tools and therapeutic agents.

69 romising biomarkers of disease and cell-free therapeutic agents.

70 types partly owing to the lack of effective therapeutic agents.

71 FZD subtypes, and the use of Wnt proteins as therapeutic agents.

72 Finally, amixicile is the first selective therapeutic agent active against bacteria internalized b

73 highlighting its potential application as a therapeutic agent against parasitic nematode infection w

74 Mambaquaretin-1 represents a promising therapeutic agent against PKDs.

75 155 and NP-1496) in encapsulated form as new therapeutic agents against H1N1 influenza virus infectio

76 uch inhibitors, if discovered, may be viable therapeutic agents against influenza.

77 hus represents a new strategy for developing therapeutic agents against TH17-mediated autoimmune dise

78 To develop candidate therapeutic agents against ZIKV, we isolated a panel of

79 amines constitute the core structure of many therapeutic agents, agrochemicals, and organic materials

80 This model can be used to test therapeutic agents aimed at chemoprevention.

81 ancer cells to arsenic trioxide, an approved therapeutic agent, along with other intracellular ROS-in

82 Thus, therapeutic agents ameliorating protein folding or the U

83 technology and as a potential source for new therapeutic agents and drug leads.

84 terest for developing novel phytosanitary or therapeutic agents and products with industrial applicat

85 ted by many factors, such as the presence of therapeutic agents and the complex nature of the syndrom

86 he development of countermeasures (vaccines, therapeutic agents, and diagnostic assays), infrastructu

87 uctural motif in bioactive natural products, therapeutic agents, and molecular catalysts, motivating

88 e modification of chiral catalyst templates, therapeutic agents, and natural products.

89 (CFPS) has the potential to produce enzymes, therapeutic agents, and other proteins, while circumvent

90 esidual disease, assess tumour resistance to therapeutic agents, and potentially screen individuals f

91 threats, such as designer drugs, biological therapeutic agents, and technologies.

92 racted considerable attention as targets for therapeutic agents, and thus mechanism-based inhibitors

93 , pathophysiology, epidemiology, assessment, therapeutic agents, and treatment strategies together wi

94 One group of therapeutic agents, antisense and oligonucleotides and s

95 , biodistribution, and clearance profiles of therapeutic agents are key factors relevant to their eff

96 f therapy for Hodgkin's lymphoma (HL), novel therapeutic agents are needed for patients with refracto

97 (CCA) are resistant to chemotherapy, so new therapeutic agents are needed.

98 el targets for the development of additional therapeutic agents are urgently needed.

99 Therapeutic agents are urgently required to cure several

100 Several antibody-based therapeutic agents as well as vaccine and T-cell therapi

101 d ion channels are of particular interest as therapeutic agents, as they modulate receptor activity w

102 has been proposed as means of concentrating therapeutic agents at a target site and the success of t

103 is a pressing need to develop new antifungal therapeutic agents because of toxicity and resistance to

104 iology platforms for the production of novel therapeutic agents, biofuels, and commodity chemicals.

105 not only facilitate the delivery of multiple therapeutic agents, but also help bypass MDR pathways, w

106 tinoic acid (atRA) is one of the most potent therapeutic agents, but extensive toxicity caused by nuc

107 diverse microorganisms and may be useful as therapeutic agents by degrading biofilms and attenuating

108 will facilitate the development of anti-CSFV therapeutic agents by targeting host factors and may pro

109 To treat this residual disease, therapeutic agents can be administered by either intrave

110 The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the

111 e therapy for two new targets and associated therapeutic agents: cyclin-dependent kinase inhibitors a

112 icate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory path

113 Local and controlled delivery of therapeutic agents directly into focally afflicted tissu

114 veals the potential of AAD-66 as a promising therapeutic agent for AD.

115 l to be an efficacious single-molecule-based therapeutic agent for CF.

116 MRSA survival, it can serve as an important therapeutic agent for combination therapy.

117 lineages and implies that DSP may serve as a therapeutic agent for dentin-pulp complex regeneration i

118 ease progression, thus making it a potential therapeutic agent for DMD.

119 s randomized, controlled trial of a putative therapeutic agent for EVD, although the estimated effect

120 Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporos

121 demonstrate that LY500307 has potential as a therapeutic agent for GBM.

122 proof of concept for H3B-6527 as a candidate therapeutic agent for HCC cases that exhibit increased e

123 LJ001 may be useful as a preventative and/or therapeutic agent for infections by enveloped viruses in

124 irions, suggesting the use of metformin as a therapeutic agent for KSHV infection and replication.

125 The latter proposes AR-12 to be a potential therapeutic agent for neurodegenerative disorders.

126 cal development of kisspeptin as a potential therapeutic agent for patients with common disorders of

127 hypertension, could be repurposed as a novel therapeutic agent for patients with D1R-expressing tumor

128 IL28 might be developed as a therapeutic agent for patients with IBD.

129 an be useful as a food supplement, a natural therapeutic agent for preventing and treating cognitive

130 f the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer.

131 (177)Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patie

132 results suggest that SAHA could be used as a therapeutic agent for the management of OA.

133 qqi that proposes the use of vorinostat as a therapeutic agent for the management of osteoarthritis.

134 a establish miR-138 inhibitor as a potential therapeutic agent for the prevention of the bone loss as

135 d inflammation, but also provide a potential therapeutic agent for the prevention of wear debris-indu

136 hese findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bon

137 e results suggest that MB has potential as a therapeutic agent for the treatment of acute WD.

138 This suggests that Myr might be a potential therapeutic agent for the treatment of DCM.

139 N4924 might be further developed as a potent therapeutic agent for the treatment of gastric cancer.

140 that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, a

141 icity in mice, suggesting its potential as a therapeutic agent for the treatment of melanoma and prob

142 sion of PA, and oxamate might be a promising therapeutic agent for the treatment of PA.

143 ntial drug target for developing a selective therapeutic agent for the treatment of psoriasis.

144 ovide a rationale for using minocycline as a therapeutic agent for treating ischemic retinal degenera

145 hermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2

146 trol has long been thought as an interesting therapeutic agent for various diseases including inflamm

147 XR agonists are currently being evaluated as therapeutic agents for a number of hepatic diseases due

148 e (MAGL) inhibitors are considered potential therapeutic agents for a variety of pathological conditi

149 earchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applica

150 Thus, CYP1B1 may serve as a target for therapeutic agents for AAA in males.

151 d functional regulatory cells could serve as therapeutic agents for autoimmune diseases, such as MS.

152 ormation necessary to develop treatments and therapeutic agents for biofilm-related infections and ma

153 arboplatin, and oxaliplatin) are widely used therapeutic agents for cancer treatment.

154 rationale for developing TCRm antibodies as therapeutic agents for cancer, offer mechanistic insight

155 etylase (HDAC) inhibitors have proven useful therapeutic agents for certain hematologic cancers.

156 treat several forms of cancer, are potential therapeutic agents for individuals with extracranial AVM

157 road implications for the development of new therapeutic agents for infectious disease.

158 target and AICAR and metformin as potential therapeutic agents for KSHV-associated cancers.

159 domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their me

160 latory cells represent a promising subset of therapeutic agents for multiple sclerosis.

161 erize the inhibitory properties of potential therapeutic agents for myotonic dystrophy, which is caus

162 s will eventually lead to new preventive and therapeutic agents for obesity, this will take time beca

163 -12 and the AR-14 analogue are potential new therapeutic agents for prion diseases and possibly prote

164 e under intense investigation as imaging and therapeutic agents for prostate and other cancers.

165 o disrupt this interaction may provide novel therapeutic agents for the management of IBD.

166 a potential target for development of novel therapeutic agents for the treatment of cognitive impair

167 r potential for development of promising new therapeutic agents for the treatment of diseases with la

168 se findings provide opportunities to develop therapeutic agents for the treatment of disorders with a

169 se to be exploited in the development of new therapeutic agents for the treatment of disseminated, li

170 d as a novel target for the discovery of new therapeutic agents for the treatment of drug-resistant t

171 could contribute to the development of novel therapeutic agents for the treatment of inflammatory dis

172 targeted complement inhibitors as potential therapeutic agents for the treatment of ischemic stroke

173 cin and other fluoroquinolones are important therapeutic agents for the treatment of tuberculosis, pa

174 at interfere with this process are potential therapeutic agents for treating mycobacterial diseases,

175 e suggests that PPAR agonists are attractive therapeutic agents for treating neurodegenerative diseas

176 ising for the design of original multitarget therapeutic agents for treating neurodegenerative diseas

177 ells and suggesting VPA and TSA as potential therapeutic agents for tumors with elevated levels of hT

178 inued development of mGlu5 PAMs as potential therapeutic agents for use in RS, and, more broadly, for

179 No therapeutic agent has been approved for the prevention o

180 Currently, no single therapeutic agent has been identified as synthetically l

181 validity of preclinical studies of candidate therapeutic agents has been questioned given their limit

182 g discovery including the advent of biologic therapeutic agents, has propelled Ras back to the forefr

183 larials that were once considered unsuitable therapeutic agents have been revisited to improve physic

184 te, most of the reported clinical studies of therapeutic agents have used PSMA-targeted radiometals t

185 antagonists have been developed as potential therapeutic agents, however their in vivo clinical effic

186 h antimicrobial resistance by developing new therapeutic agents, if headway is to be made against the

187 Our findings indicate NIr to be an effective therapeutic agent in a primate model of the disease and

188 warrant the exploration of TZD as preventive/therapeutic agent in HIV infection.

189 vel peptide as promising targeting probe and therapeutic agent in melanoma disease.

190 er cell lines, suggesting its potential as a therapeutic agent in Notch-associated malignancies.

191 nocytes, suggesting that HA35 may be a novel therapeutic agent in the treatment of ALD.

192 TRP mouthwash can be considered a potential therapeutic agent in the treatment of gingivitis.

193 results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.

194 molecular-weight oligomers that can act as a therapeutic agent in vitro and in vivo.

195 phocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases.

196 ty of EYA tyrosine phosphatase inhibitors as therapeutic agents in inhibiting pathological neovascula

197 new molecular target for the development of therapeutic agents in multiple sclerosis.

198 rmacological approach in the design of novel therapeutic agents in preference to compounds targeting

199 es hold promise as novel prophylactic and/or therapeutic agents in the fight against HIV-1.

200 agnitude of regional response to respiratory therapeutic agents in the lungs by using treatment respo

201 e is mounting evidence of their potential as therapeutic agents in the treatment of multiple central

202 t dopamine D2 and D3 receptors are important therapeutic agents in the treatment of Parkinson's disea

203 ntial of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.

204 scientists constantly seek for new potential therapeutic agents including nanotechnology-based photos

205 echnology of wide applicability that enables therapeutic agents, including anticoagulants, to bind to

206 ave developed resistance to a broad range of therapeutic agents, including both targeted as well as c

207 ool for customizable and precise delivery of therapeutic agents into target tissues.

208 -targeting vectors to shuttle diagnostic and therapeutic agents into tumor cells.

209 icting the response of a cancer patient to a therapeutic agent is a core goal of precision medicine.

210 eonates, for which no specific preventive or therapeutic agent is available.

211 Targeted delivery of therapeutic agents is an important way to improve the th

212 ordingly, the role of TLR agonists as cancer therapeutic agents is being revisited via the strategy o

213 The use of peptides as therapeutic agents is undergoing a renaissance with the

214 ate tumorigenesis, and escape the effects of therapeutic agents; it also promotes tumor aggressivenes

215 research, particularly in the arena of novel therapeutic agents (nonparticulate steroids and nonstero

216 A new therapeutic agent now exists to target further heart rat

217 Therapeutic agents other than antitoxin offered no clear

218 of CAD and facilitate the development of new therapeutic agents over time.

219 fic antibodies are considered attractive bio-therapeutic agents owing to their ability to target two

220 tocols that use a combination of traditional therapeutic agents paired with cell populations includin

221 As a rich source of therapeutic agents, peptide natural products usually ado

222 ines, proteases, exosomes, microvesicles, or therapeutic agents, play important and multifaceted role

223 photons have been combined with photodynamic therapeutic agents preclinically for increasing therapeu

224 cinetobacter drastically limits the range of therapeutic agents required to treat multidrug resistant

225 therapy including ixazomib with traditional therapeutic agents such as dox is a viable strategy that

226 e explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholest

227 cells were resistant to autophagy-activating therapeutic agents, such as fludarabine and the BCL2 hom

228 vivo and paved the way for the evaluation of therapeutic agents targeted at reducing plaque vulnerabi

229 s allows sustained site-specific delivery of therapeutic agents targeted to inhibit localized neointi

230 otemporal controlled delivery and release of therapeutic agents, targeted and controlled nanosystems,

231 In conclusion, Z-TMS appears to be a unique therapeutic agent targeting HCV and concurrently elimina

232 tool to support the development of any novel therapeutic agent targeting pathological forms of tau.

233 nlocks new strategies for the development of therapeutic agents targeting individual functions.

234 they thus unveil new avenues for developing therapeutic agents targeting induction of host cell oxid

235 ources could be predictive of sensitivity to therapeutic agents targeting the PD-L1/PD-1 axis.

236 uss radiohalogenated versions of imaging and therapeutic agents targeting the prostate-specific membr

237 Therapeutic agents targeting these cytokines and/or thei

238 mplications for the development of effective therapeutic agents targeting tumor-initiating cells.

239 A therapeutic agent that acts on the renin-angiotensin-ald

240 ts with IBD, 1,25D appears as an interesting therapeutic agent that inhibits the IL-23 receptor pathw

241 sc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprot

242 trogen, 17beta-estradiol (E2), is a powerful therapeutic agent that plays a critical role in bone hom

243 Conclusions Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diar

244 Therapeutic agents that activate TNF-related apoptosis-i

245 , microRNAs (miRNAs) could serve as adjuvant therapeutic agents that alter cellular sensitivity to ra

246 Thus, there is an unmet need for therapeutic agents that are able to block or slow apopto

247 ndations on a more "tailored" use of the new therapeutic agents that are currently tested in clinical

248 viduals suffering from chronic pain, and new therapeutic agents that are more effective, safer, and d

249 ing of the MET receptor tyrosine kinase, but therapeutic agents that can broadly block HGF ligand bin

250 hus, there is a critical need to develop new therapeutic agents that can effectively eliminate drug-r

251 dy will be valuable for the future design of therapeutic agents that can selectively enhance A1R-medi

252 naling is necessary for the future design of therapeutic agents that can selectively enhance A1R-medi

253 e blood brain barrier (BBB), and the lack of therapeutic agents that can selectively target the intra

254 As a result, therapeutic agents that disrupt this signaling pathway h

255 focal osteolysis, leading to development of therapeutic agents that either directly block the bone-r

256 These sites may be appropriate targets for therapeutic agents that inhibit or potentiate, respectiv

257 uture high throughput screening of potential therapeutic agents that may reverse phenotypic and behav

258 brain tissues are too fast for an effective therapeutic agent, the pharmacokinetic profile of PF-367

259 fections in asthmatic patients and potential therapeutic agents, the microbiome, novel genetic associ

260 y and although they are potential targets of therapeutic agents, there are no structures of human P2X

261 Targeted delivery of a therapeutic agent to a site of pathology to ameliorate d

262 data suggest that pirfenidone is a potential therapeutic agent to ameliorate fibrosis in cGVHD.

263 S100A1 has been suggested as a therapeutic agent to enhance myocyte Ca(2+) cycling in h

264 oof of concept defining C1572 as a promising therapeutic agent to eradicate CSCs for drug-resistant T

265 nosine analogs, may represent a new class of therapeutic agent to fight type 2 diabetes.

266 ndicate that CFI-402257 is a promising novel therapeutic agent to improve the efficacy of the current

267 is in vitro and in vivo and has promise as a therapeutic agent to limit the development of postsurgic

268 ader applicability of using miR-193a-3p as a therapeutic agent to target KRas-mutant cancer.

269 ty in vivo, thus providing a bona fide novel therapeutic agent to treat enterohepatic disorders such

270 nical proof of concept for IT-901 as a novel therapeutic agent to treat human lymphoid tumors and ame

271 Quininib has potential as a novel therapeutic agent to treat ocular neovascular pathologie

272 sis in immunocompromised patients is lack of therapeutic agents to clear chronic infection and stop t

273 omedicine that is able to target and deliver therapeutic agents to diseased bone sites could potentia

274 be a promising target for the development of therapeutic agents to limit tumor cell growth in bone me

275 , which may promote the development of novel therapeutic agents to mimic the protective effects of LS

276 nti-CD38 chitosan NPs specifically delivered therapeutic agents to MM cells improving therapeutic eff

277 erited aortopathies has identified potential therapeutic agents to prevent thoracic aortic disease.

278 ng need to develop strategic combinations of therapeutic agents to prevent type 1 diabetes (T1D) or t

279 also identified small molecules as potential therapeutic agents to reverse beta-defensin 1-associated

280 alpha as well as other PPARs may lead to new therapeutic agents to slow or halt the progression of am

281 effective and sustained targeted delivery of therapeutic agents to solid tumors have revolutionized c

282 A treatment includes ineffective delivery of therapeutic agents to the resident chondrocytes in the a

283 However, the effective delivery of therapeutic agents to these cells requires an understand

284 inhibitors may be used as potential adjuvant therapeutic agents to treat increased vascular leakage o

285 these promising lead compounds as potential therapeutic agents to treat Lassa hemorrhagic fever.

286 The compounds have potential as therapeutic agents to treat S. aureus infections, and pu

287 etase inhibitor may be an effective clinical therapeutic agent towards AD.

288 Polymyxins are often last-line therapeutic agents used to treat infections caused by mu

289 cells can resist the effects of DNA-damaging therapeutic agents via utilization of DNA repair pathway

290 nd improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation

291 68)Ga-NODAGA-JR11 or (68)Ga-OPS202) and as a therapeutic agent when labeled with (177)Lu ((177)Lu-DOT

292 a17-21 P has significant promise as a new AD therapeutic agent which targets the Abeta related apoE p

293 This combination of therapeutic agents, which have already been tested and a

294 ies against CHIKV as viable prophylactic and therapeutic agents will be discussed.

295 e safety and efficacy is to deliver a proven therapeutic agent with a targeting ligand that exhibits

296 ite of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action

297 ASOs are a useful class of therapeutic agents with broad utility.

298 id receptors, have been proposed as possible therapeutic agents with enhanced selectivity.

299 investigations have focused on HIF-targeting therapeutic agents, with encouraging preclinical and cli

300 may affect the feasibility of delivering new therapeutic agents within the cost constraints of antima